Format

Send to

Choose Destination
Mol Clin Oncol. 2016 May;4(5):675-681. Epub 2016 Mar 3.

Cardiotoxicity associated with targeted cancer therapies.

Author information

1
Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
2
Department of Pathology, Baylor Scott and White Memorial Hospital, Texas A&M Health Science Center, Temple, TX 76508, USA.

Abstract

Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in carcinogenesis and tumor spread are inhibited. Targeted cancer therapy has fewer adverse effects on normal cells and is considered to be the future of chemotherapy. However, targeted cancer therapy-induced cardiovascular toxicities are occasionally critical issues in patients who receive novel anticancer agents, such as trastuzumab, bevacizumab, sunitinib and imatinib. The aim of this review was to discuss these most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events, as well as summarize their respective molecular mechanisms of cardiovascular adverse effects.

KEYWORDS:

bevacizumab; imatinib; sunitinib; trastuzumab; tyrosine kinase inhibitor

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center